cardiomyopathy
A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another focused on polyneuropathy.
NHGRI to Fund Population Genomic Screening in Primary Care Network With $38.1M
Starting next year, the network will implement a population genomic screening pilot program for common, actionable genomic conditions in a primary care setting over five years.
FDA Lifts Hold on 4D Molecular Therapeutics' Fabry Disease Cardiomyopathy Gene Therapy Trial
Now that the clinical hold has lifted, 4DMT said it expects to resume enrollment in the Phase I/II trial evaluating 4D-310 in the second half of 2024.
Lexeo, Weill Cornell Data Rights Pact to Speed Development of FA Cardiomyopathy Gene Therapy
The firm has in-licensed data rights on LX2006 that will allow it to double the number of evaluable patients in clinical trials.
In Brief This Week: Lexeo Therapeutics, GeneVentiv Therapeutics, Allarity Therapeutics
News items for the week of April 15, 2024.